Evidence map›Paper›PMID 42827614›Full record

ReviewFrontiers in pharmacology2026

Hantavirus as a persistent zoonotic risk: epidemiology and current pharmacological management.

Salvatore Di Maria, Alessio Provenzani

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Salvatore Di MariaSchool of Specialization in Hospital Pharmacy, University of Catania, Catania, Italy.
Alessio ProvenzaniIRCCS ISMETT, Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hantaviruses are emerging rodent-borne zoonotic viruses that continue to pose a public health concern despite their relatively low incidence in humans. The 2026 Methods: A review of the recent literature was performed, focusing on zoonotic transmission, the role of companion animals, current and emerging therapeutic strategies, infections in immunocompromised and solid-organ transplant recipients, and the implications of the 2026 international outbreak. Results: Although the sentinel hypothesis remains plausible, companion animals are not natural reservoirs, and preliminary evidence suggests that their exposure may reflect local hantavirus circulation, while pet rats have emerged as an important source of Conclusion: Recent evidence broadens the clinical and public health relevance of hantaviruses beyond their traditional framing as rodent-borne zoonoses. Advances in targeted therapeutics, integrated surveillance, and One Health preparedness will be pivotal to improving outbreak preparedness and accelerating the development of effective preventive and therapeutic strategies.

Indexed as

Andes viruscompanion animalsHantavirushemorrhagic fever with renal syndromeorthohantaviruspharmacological treatmentribavirinsolid organ transplantation

Identifiers

PMID42827614
PMCPMC13631434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.